The expression of MAPRE1 is up-regulated after cisplatin treatment, and circSOX13 elevates cisplatin resistance by promoting MAPRE1 in cisplatin resistant NSCLC cell lines and tumors. Here, MAPRE1 is linked to non-small cell lung carcinoma.